KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Amortization of Deferred Charges: 2011-2021

Historic Amortization of Deferred Charges for TherapeuticsMD (TXMD) over the last 8 years, with Dec 2021 value amounting to $5.7 million.

  • TherapeuticsMD's Amortization of Deferred Charges rose 74.81% to $2.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was $21.1 million, marking a year-over-year increase of 317.92%. This contributed to the annual value of $5.7 million for FY2021, which is 124.68% up from last year.
  • Latest data reveals that TherapeuticsMD reported Amortization of Deferred Charges of $5.7 million as of FY2021, which was up 124.68% from $2.5 million recorded in FY2020.
  • TherapeuticsMD's 5-year Amortization of Deferred Charges high stood at $5.7 million for FY2021, and its period low was $269,859 during FY2018.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $2.5 million (2020), whereas its average is $3.0 million.
  • Data for TherapeuticsMD's Amortization of Deferred Charges shows a peak YoY spiked of 217.20% (in 2019) over the last 5 years.
  • TherapeuticsMD's Amortization of Deferred Charges (Yearly) stood at $269,859 in 2018, then spiked by 217.20% to $856,000 in 2019, then surged by 195.79% to $2.5 million in 2020, then spiked by 124.68% to $5.7 million in 2021.